Many small-molecule inhibitors that solely target TGFβ or BMP kinase receptors have been investigated for metastatic cancers in preclinical studies, and two of them are currently investigated in clinical trials [1, 12, 13, 28–30]. The gene discussed is TGFB1; the disease is metastatic malignant neoplasm.